Neuralink PRIME Study Enrolls 21+ Patients and Announces High-Volume Production Plans
Summary
Neuralink announced that its PRIME study has enrolled more than 21 patients with its N1 brain-computer interface implant. The company also unveiled plans for high-volume production and robot-assisted implantation procedures targeting under 30 minutes per surgery. The N1 implant uses 1,024 electrodes to record and stimulate neural activity, enabling patients with paralysis to control digital devices with their thoughts.
Why it matters
The enrollment of over 21 patients represents significant progress in Neuralink's clinical program, making it one of the largest implanted BCI studies underway. The announcement of high-volume production plans signals a shift toward commercialization readiness. The company's robotic surgery approach could reduce implantation time and cost, potentially making the technology more accessible to patients with paralysis and other neurological conditions.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial